Cyclezyme to buy Ragn-Sells melanin patent, pays via shares for 7.9% stake

• Cyclezyme agreed to acquire the SE 540415 C2 patent and related IP for a biotech melanin production process from Ragn-Sells.
• Deal aims to add a new product platform, strengthening control over development and potential commercialization across cosmetics, biomedical materials, water treatment.
• Consideration set by a 10-day VWAP formula tied to a post-transaction 7.9% equity stake for Ragn-Sells.
• Completion targeted about two weeks from signing, subject to customary corporate and regulatory steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cyclezyme AB published the original content used to generate this news brief via Cision (Ref. ID: 202609061245BITN____UKPR__SV_20260812-BIT-6750-0) on September 06, 2026, and is solely responsible for the information contained therein.